Authors
Latest:
Closing Thoughts on Recent Data in GI CancerRohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ASCO Annual Meeting.
Latest:
Dr. Ballinger Shares Her Top News From ASCO 2024Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.
Latest:
Advice for Community Oncologists Treating Metastatic Castration-Resistant Prostate CancerDr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.
Latest:
Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCCManojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.
Latest:
Unmet Needs in R/R DLBCLDr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.
Latest:
Selecting Treatment for Late-Stage SCLCAfshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.
Latest:
Transforming Neuroendocrine Tumor Treatment With Lutetium OxodotreotideAman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.
Latest:
Molecular Characteristics Determine Subtypes of Small Cell Lung CancerQian Wang, MD, MPH, discusses the progress of research into the molecular pathways responsible for developing small cell lung cancer.
Latest:
Nirogacestat Shows Improved PFS and Quick Response in Desmoid TumorsMark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat.
Latest:
Examining Pelabresib for Patients With MyelofibrosisJoseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.
Latest:
Machine Learning Transforms Multicancer Detection TestsThis review discusses the current state of multicancer early detection tests, the role of machine learning in their development, and their implications for oncology practice and patient care.
Latest:
Immunotherapy Offers Hopeful Outcomes in Nonmelanoma Skin CancersNew and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.
Latest:
ctDNA Is Improving Oncology Care and Should Be Part of the Standard of CareMany oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.
Latest:
TAR-210's Potential to Improve Outcomes in Intermediate-Risk NMIBCRoger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations.
Latest:
Sequencing Therapy With Novel Agents in Metastatic CholangiocarcinomaClinical pearls regarding molecular testing and treatment selection in metastatic cholangiocarcinoma.
Latest:
Phase 3 Study Demonstrates Intracranial Response in ALK+ NSCLCBenjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.
Latest:
McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid CancerDuring a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.
Latest:
Using MRD to Predict Outcomes in Acute Myeloid LeukemiaSangeetha Venugopal, MD, MS, discusses how measurable residual disease is used during the course of treatment of AML.
Latest:
Overall Experience: Elevating the Patient EncounterBranding in the health care industry should prioritize communicating empathy and care through every touchpoint.
Latest:
Pluvicto Approval Launches Theranostics in Prostate CancerAshok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Latest:
Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AMLDanielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Latest:
RAD-SG Trial Evaluates RADiation Therapy and Sacituzumab Govitecan in MIBCOmar Mian, MD, PhD, provides an overview of the RAD-SG trial of RADiation therapy given with sacituzumab govitecan for bladder preservation in patients with muscle-invasive bladder cancer, which is currently in progress.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Bhatt Recaps Trial of Ruxolitinib in Steroid Refractory Sclerotic cGVHDVijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.
Latest:
Non-Invasive Biomarkers: Key to Better Pancreatic Cancer OutcomesAjay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.
Latest:
Investigating KRAS/TP53 Co-Alterations in Pancreatic CancerJashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.
Latest:
EPIC-A Trial Insights on Cemiplimab and Chemotherapy in Penile CarcinomaAmarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, discusses some of the most promising findings from the EPIC-A trial of cemiplimab with chemotherapy in treating locally advanced or metastatic penile carcinoma.
Latest:
Optimizing the Management of Melanoma: Future Directions in CareClosing out his discussion on the management of metastatic melanoma, expert oncologist Sajeve Thomas, MD, summarizes unmet needs and looks toward future evolutions in the treatment paradigm.
Latest:
Challenging Barriers to Community Oncology CareDipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.
